Dr. Gronchi on the Results of the TRASTS Trial in Soft Tissue Sarcoma

October 23, 2020
Alessandro Gronchi, MD
Alessandro Gronchi, MD

Alessandro Gronchi, MD, discusses ​the results of the ​phase 2 TRASTS trial in soft tissue sarcoma.

Alessandro Gronchi, MD, chair of Sarcoma Service, IRCCS Foundation National Cancer Institute, Milan, Italy, discusses ​the results of the ​phase 2 TRASTS trial in soft tissue sarcoma.

The international, prospective TRASTS study, which was presented during the 2020 ASCO Virtual Scientific Program, ​evaluated the utility of trabectedin (Yondelis) in combination with radiation therapy ​in patients with localized myxoid liposarcoma.

Prior data showed that trabectedin alone induced tumor shrinkage in 40% to 50% of patients in this population, Gronchi says. Additionally, radiation therapy ​alone induces tumor shrinkage in about 40% of patients.

Findings from the study showed that 53% of patients ​treated had tumor shrinkage ​with 10% or less viable tumor remaining​, says Gronchi.

​Additionally, ​30% of patients achieved a partial response and 70% achieved stable disease with the combination, ​Gronchi adds.

Ultimately, the combination of trabectedin and radiation therapy appears to be a feasible and well-tolerated regimen in patients with localized myxoid liposarcoma, Gronchi concludes.


x